Overall verdict
Neutral
6.0/10
1-year performance
+14.34%
Score breakdown
Up 14.3% over 1 year, 44% of the 52-week range.
Strongest: Shareholder return 7.2/10. Weakest: Financial strength 2.6/10.
27 analysts, target +0.3% vs the price.
CVS Health Corporation provides health solutions in the United States. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental, and behavioral health plans ; medical management capabilities ; Medicare Advantage and Medicare Supplement plans ; prescription drug plans (PDPs) ; and Medicaid health care management services.
It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail-order pharmacy, clinical services, disease management, medical spend management services, and pharmacy and other administrative services.
It serves employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, CMS, plans offered on public health insurance exchanges, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products.
This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
J. Joyner
Founded
1963
Employees
300 000
Revenue / employee
1.3M USD
Next earnings
November 4, 2026 (estimated)
Institutional holders
- BlackRock, Inc.9.83%
- VANGUARD CAPITAL MANAGEMENT LLC6.64%
- Capital World Investors5.98%
- STATE STREET CORP4.81%
- Dodge & Cox3.99%
- WELLINGTON MANAGEMENT GROUP LLP2.70%
- GEODE CAPITAL MANAGEMENT, LLC2.38%
- FMR LLC2.31%
- VANGUARD PORTFOLIO MANAGEMENT LLC2.12%
- Other institutions49.89%
- Rest of the register9.35%
2060 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
110.68 USD
52-week low
69.51 USD
1-year performance
14.34%
Rising
Year-to-date performance
8.30%
Rising
Drawdown
-20.87%
Marked drawdown
Position in the 52-week range
44% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned less, while shaking 2.2 times harder.
10,000 € placed at the end of September 2009 are worth today
| CVS Health | 49 620 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 2.2 times as much as the world ETF.
- Worst fall:-57 % between August 2022 and December 2024. 10,000 € placed at the top fell to 4 336 €. The world ETF, at worst: -34 %. Back to its high in 18 months.
CVS Health earned less than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- CVS Health: 49 620 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 126.58 USD - 148.00 USD (2 methods agree)
The price implies growth of -5.10% per year; the company grows at -10.00%.
Gross margin 14.2%, net margin 1.2%, ROIC 3.2%, ROE 6.2%.
Net margin
1.18%
Low
Sector 3.25%|S&P 12.97%
Gross margin
14.16%
Low
Return on equity (ROE)
6.23%
Fair
Sector 7.23%|S&P 16.52%
Return on invested capital (ROIC)
3.25%
Fair
Free cash flow margin (FCF)
2.83%
Low
Profit-to-cash conversion (FCF conversion)
2.40x
High
Margin stability
0.8 pts
Very steady
Revenue to net income
Growth
5.9/10Revenue up 7.2% over 1 year, 8.4% a year over 5, EPS -23.9% a year over 5.
Revenue (trailing 12 months)
415Md USD
Revenue growth (1y)
7.24%
Moderate
Revenue growth (3y)
24.57%
Solid
EPS growth (1y)
187.93%
Hyper-growth
EPS CAGR (5y)
-23.94%
Declining
EPS revisions (3 months)
8.20%
Sharply revised up
Valuation
6.1/10P/E 23.1x, forward P/E 12.7x, EV/EBITDA 12.3x, PEG 4.05. The multiple sits in the 93th percentile of its own 5-year history.
P/E (TTM)
23.1x
Fair
Sector 30.9x|S&P 23.0x
Forward P/E
12.7x
Cheap
EV / EBITDA
12.3x
Fair
Sector 13.1x|S&P 14.5x
PEG
4.05
Very expensive
Sector 1.23|S&P 0.86
Fair value (reverse DCF)
137.29 USD
Deeply undervalued
P/E vs its own 5-year history
among the 7% highest valuations
At its historical high
Market cap
110Md USD
Financial strength
2.6/10Cash covers 18.3% of the debt, net debt/EBITDA 4.1x.
Net debt / EBITDA
4.1x
Stretched
Gearing (net debt / equity)
78.03%
Tight
Cash
14.0Md USD
Cash / market cap
12.71%
Solid
Cash / total debt
18.29%
Tight
Interest coverage
2.7x
Tight
Net debt
62.3Md USD
Equity
79.9Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 85.05 USD
- MM2092.83
- MM5097.42
- MM20087.45
- RSI 1423.1
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.81%
200-day average slope, 3 months
+8.21%
50-day average slope, 1 month
-4.21%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.34 % per day
Volatility change
-24.92%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 6.87 (15) | 8.04 (25) | 417 804 (21) | 19 966 (11) | 8 875 (10) |
| 2027 | 7.23 (16) | 8.53 (26) | 429 901 (22) | 20 738 (12) | 9 319 (11) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 24, 2026.
Same sub-industry: 77 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HNGE | 7.2 | 6.6 | 7.4Md USD | 71.1x | 14.8 % | 53.0 % | 29.3 % | -3.8x | 3.8 % | 55.7 % | ||
| 2 | CI | 6.9 | 7.0 | 70.9Md USD | 11.1x | 2.3 % | 6.5 % | 9.3 % | 1.8x | 12.9 % | -8.0 % | ||
| 3 | LH | 6.7 | 5.9 | 24.7Md USD | 25.1x | 7.0 % | 5.8 % | 6.8 % | 2.4x | 4.7 % | 10.4 % | ||
| 4 | DVA | 6.5 | 6.4 | 11.7Md USD | 15.4x | 5.9 % | 5.2 % | 6.9 % | 4.5x | 13.8 % | 32.3 % | ||
| 5 | DGX | 6.5 | 5.8 | 25.7Md USD | 24.7x | 9.2 % | 10.2 % | 7.9 % | 2.8x | 5.2 % | 26.9 % | ||
| 6 | BTSG | 6.4 | 4.9 | 11.0Md USD | 41.7x | 1.7 % | 23.0 % | 5.7 % | 4.6x | 3.6 % | 102.1 % | ||
| 7 | CVS | 6.0 | 5.1 | 110Md USD | 23.1x | 1.2 % | 7.2 % | 3.2 % | 4.1x | 10.7 % | 14.3 % | ||
| 8 | FME | 5.3 | 6.7 | 12.0Md USD | 11.8x | 4.8 % | 1.4 % | 4.3 % | 2.7x | 17.0 % | -10.0 % | ||
| 9 | GH | 4.7 | 2.6 | 23.7Md USD | Not meaningful (loss) | -38.3 % | 44.3 % | -37.0 % | -1.5x | -1.0 % | 189.0 % |
